Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Item No. 21916

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
2-(Phosphonomethyl)-pentanedioic acid (2-PMPA) is a potent inhibitor of glutamate carboxypeptidase II (GCP II), also known as N-acetylated α-linked dipeptidase (NAALADase), with a Ki value of 98 pM for release of glutamate from the NAALADase peptide substrate N-acetylasparatylglutamate (NAAG).1 It is selective for GCP II/NAALADase over a panel of 100 receptors, transporters, ion channels, and enzymes at a concentration of 10 μM.2 2-PMPA is neuroprotective against hypoxia (EC50 = 8.4 μM), but not veratridine-induced injury, in neuron-enriched primary cultures from rat embryo cerebellum.3 In vivo, 2-PMPA reduces neuronal cell death induced by middle cerebral artery occlusion via increases in NAAG expression and reduction of glutamate in rats.2 2-PMPA (100 mg/kg) blocks the conditioned place preference response to cocaine, but not food, in male rats.4 It reduces the number of flinches induced by formalin injection into the footpad of mice when administered at a dose of 10 μg per animal, an effect that is reversed by the group II metabotropic glutamate receptor antagonist LY341495.5 2-PMPA also decreases severity and delays onset of experimental autoimmune encephalomyelitis (EAE) in mice.6
WARNING This product is not for human or veterinary use.
1. Hydrolysis of the neuropeptide N-
2. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat. Med. 5(12), 1396-1402 (1999).
3. Neuroprotection produced by the NAALADase inhibitor 2-
4. Expression and acquisition of the conditioned place preference response to cocaine in rats is blocked by selective inhibitors of the enzyme N-
5. Intracerebroventricular administration of N-
6. Blocking glutamate carboxypeptidase II inhibits glutamate excitotoxicity and regulates immune responses in experimental autoimmune encephalomyelitis. FEBS J. 283(18), 3438-3456 (2016).